Full Press Release Details
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
MIRM Positive Sentiment
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Key Takeaway: Mirum Pharmaceuticals has announced that the primary endpoint has been met in the Phase 3 EXPAND study of LIVMARLI (maralixibat) for treating ultra-rare cholestatic liver diseases. This achievement indicates significant progress in the development of this treatment, which could benefit patients suffering from these conditions.
Market Sentiment Analysis
POSITIVE FACTORS
- Primary endpoint met in Phase 3 study.
- LIVMARLI shows promise for ultra-rare cholestatic liver diseases.
- Positive implications for patient outcomes.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~36 mo
Minimal dilution risk
Lead asset
Blinded CDCA
Phase 3 · CTX
Frequently Asked Questions
What is the primary endpoint of the EXPAND study?
The primary endpoint met in the Phase 3 EXPAND study of LIVMARLI.
What condition does LIVMARLI target?
LIVMARLI targets ultra-rare cholestatic liver diseases.
Who announced the Phase 3 study results?
Mirum Pharmaceuticals announced the results of the Phase 3 study.
What is LIVMARLI's active ingredient?
The active ingredient in LIVMARLI is maralixibat.